Pipeline

Programs

Athos Therapeutics is currently advancing one preclinical program for patients with Ulcerative Colitis & Crohn’s Disease. Furthermore, Athos is pursuing additional discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases.

Disease

Drug

Discovery

Preclinical

Phase 1

Phase 2

Inflammatory Bowel Disease

ATH-001

Inflammatory Bowel Disease

ATH-063

Systemic Lupus Erythematosus

ATH-071

Cancer

ATH-055